Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218…

Overview of attention for article published in Journal of Clinical Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs: 1 blog
twitter: 59 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 66 Mendeley

So far, Altmetric has seen 72 X posts from 59 X users, with an upper bound of 199,271 followers.

@donalb5 @SuyogCancer @BatistaTP @RParejaGineOnco @OncoNerd @IJGConline @IJGCfellows @leitaomd @pedroramirezMD @AndreasObermair @zivanovicmd @dviverosc @julianalrc @oncohoegl @indepso @ESGO_society @nagustiga @danielsanabrias @tumastologo1 @PSOGI_EC @al…

RT @DrSGraff: First, @drdonsdizon will present KELIM: Identification of Patients W/Ovarian Cancer Experiencing Highest Benefit From Bevaciz…

First, @drdonsdizon will present KELIM: Identification of Patients W/Ovarian Cancer Experiencing Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity: GOG-0218 Validation Study #BrownJC #gyncs…

OVARIAN: maintenance VEGF inhibition with bevacizumab appears to benefit patients with poor responses to chemotherapy, as assessed by CA125 dynamics. https://t.co/hqaq0ysadH

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 68 additional X posts.